Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor that blocks BCR-dependent NF-κB activation, is one of the candidates for tailored medicine for DLBCL patients, due to its strong effects in DLBCL-derived cell lines. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.